Examining the Effect of PARP-1 Inhibitors on Transcriptional Activity of Androgen Receptor in Prostate Cancer Cells.

Abstract

Since the early 1940s, androgen ablation has been the cornerstone of treatment for prostate cancer (PC). Importantly, androgen receptor (AR) signaling is vital not only for the initiation of PC, which is initially androgen-dependent, but also for castration-resistant disease. Recent studies demonstrated clear promise of the poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors for targeting prostate cancer cells harboring mutations in DNA damage-repair genes. In addition, it has been established that PARP-1 inhibition suppresses growth of AR-positive prostate cancer cells in cell and animal models. Thus, prostate cancer represents a particularly promising disease site for targeting PARP-1, given that both DNA repair and AR-mediated transcription depend on PARP-1 function. Here, we describe the development and use of cell-based assay to evaluate the impact of PARP-1 inhibitors on the AR signaling in prostate cancer cells.

• Authors: Peter Makhov, Rushaniya Fazliyeva, Antonio Tufano, Robert G Uzzo, Vladimir M Kolenko
• Journal: Methods in molecular biology (Clifton, N.J.) (Methods Mol Biol) Vol. 2609 Pg. 329-335 ( 2023) ISSN: 1940-6029 [Electronic] United States
• PMID: 36515844 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: © 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Chemical References

• Poly(ADP-ribose) Polymerase Inhibitors
• Receptors, Androgen
• Androgens

Topics

• Humans
• Male
• Animals
• Poly(ADP-ribose) Polymerase Inhibitors (pharmacology, therapeutic use)
• Receptors, Androgen (genetics)
• Androgens
• Prostate
• Prostatic Neoplasms (drug therapy, genetics)